Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study

Chi-Hung Liu1,2, Tsong-Hai Lee1,2, Yu-Sheng Lin3,4, Pi-Shan Sung5, Yi-Chia Wei6,7 and Yan-Rong Li8*

Abstract

Background and aim: Peroxisome proliferator-activated receptor-γ (PPAR-γ) modulating treatment may have cardiovascular benefits in type 2 diabetes mellitus (T2DM) patients after ischemic stroke (IS). However, whether there are additional benefits from intensive PPAR-γ modulating treatments in Asian patients with T2DM and hypertension (HTN) after IS remains unknown.

Methods: Between 2001 and 2013, patients admitted due to IS were identified from the National Health Insurance Research Database of Taiwan. Patients with T2DM and HTN using angiotensin receptor blockers were further included. Eligible patients were divided into two groups: (1) pioglitazone and (2) non-pioglitazone oral anti-diabetic agent groups. Propensity score matching (1:2) was used to balance the distribution of baseline characteristics, stroke severity and medications. The primary outcome was recurrent IS. Subgroup analysis for recurrent IS in pioglitazone and/or telmisartan users, the trend of IS risks across different PPAR-γ intensity treatments, and dose-dependent outcomes across different pioglitazone possession ratios were further studied. Statistical significance was set at $p < 0.05$ and $p < 0.1$ for clinical outcomes and interaction of subgroup analyses, respectively.

Results: There were 3190 and 32,645 patients in the pioglitazone and non-pioglitazone groups. Patients of the pioglitazone group had a lower risk of recurrent IS (subdistribution hazard ratio, 0.91; 95% confidence interval 0.84–0.99). Pioglitazone was also associated with reduced recurrent IS in patients who also used telmisartan ($p$ for interaction $= 0.071$). A graded correlation was found a borderline significant trend between the intensity of PPAR-γ therapy and following IS ($p = 0.076$). The dose-dependent outcome also showed that a borderline significant trend that higher pioglitazone possession ratio was associated with a lower risk of recurrent IS ($p = 0.068$).

Conclusions: The current study suggests that the use of pioglitazone in type 2 diabetic and hypertensive IS patients is associated with fewer recurrent IS events in an Asian population. Concurrent telmisartan use or a higher pioglitazone possession ratio may have a trend of increased pleiotropic effects, which could possibly be related to higher PPAR-γ effects. Future studies are warranted to confirm or refute the clinical effects and the possible mechanism of more intensive PPAR-γ-modulating treatments.

© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Stroke is one of the most common causes of death and disability worldwide, and risk factor modification is crucial for the prevention of ischemic stroke (IS). Among the well-established modifiable risk factors, diabetes mellitus (DM) and insulin resistance (IR) are independent risk factors for worse clinical outcomes of acute IS [1, 2], and long-term stroke recurrence [3]. IR may promote platelet aggregation, accelerate atherosclerosis, impair cerebrovascular reserve function, and cause endothelial dysfunction [3]. Therefore, patients with IR often have higher incidence rates of vascular events, including recurrent IS [3, 4]. Peroxisome proliferator-activated receptor-γ (PPAR-γ) is a known essential mediator for the maintenance of whole body insulin sensitivity [5]. Biochemical and metabolic regulators of PPAR-γ have been considered as therapeutic targets in cardiovascular diseases [6]. A previous Cochrane review demonstrated that PPAR-γ agonists may improve insulin sensitivity and probably reduce recurrent strokes and total cardiovascular death events [4].

Pioglitazone, which is a member of the thiazolidinedione class of drugs, is a potent PPAR-γ agonist and theoretically has protective vascular effects due to its mechanism of action [7, 8]. However, pioglitazone did not show any benefit compared to sulfonylurea in a low cardiovascular risk population in the ‘Thiazolidinediones or Sulphonylureas and Cardiovascular Accidents Intervention Trial’ [9]. For high cardiovascular risk patients, the occurrence of composite cardiovascular outcomes was lower in pioglitazone users in the ‘Insulin Resistance Intervention After Stroke’ (IRIS) study [8]. The results of meta-analyses suggested that pioglitazone could reduce the risk of stroke in IS patients with IR or DM [7, 8, 10, 11], but a meta-analysis study may have limitations due to the diversity of the study populations. Moreover, there are relatively limited data focusing on Asian patients from clinical trials. A Korea nested case–control study using real-world data demonstrated a benefit of pioglitazone on composite cardiovascular outcomes but not on recurrent IS in patients after acute IS [12]. It would be valuable to examine the benefits of pioglitazone in high cardiovascular risk Asian patients.

Angiotensin receptor blockers (ARBs) are anti-hypertensive drugs, which preferentially inhibit angiotensin type 1 receptors and therefore have several pleiotropic functions beyond their primary blood-pressure-lowering effects [13]. Among ARBs, telmisartan relatively yields higher PPAR-γ modulating activity and improves IR [13–17]. The safety of combining multiple PPAR-γ modulating drugs, such as pioglitazone and telmisartan, has been previously examined in animal models [18, 19]. Whether the combination results in better vascular protective effects for high-risk patients is an issue worth further investigation [13]. As to date, the answer has remained elusive [17]. This real-world study firstly examined the long-term outcomes of pioglitazone in Asian type 2 DM (T2DM) patients with hypertension (HTN) after IS. We further investigated whether intensive PPAR-γ modulating treatment, via a combination of pioglitazone and telmisartan, was associated with additional benefits beyond the target control of blood sugar and blood pressure (BP) levels in patients with T2DM and HTN.

Methods

Data source and patient identification

The present retrospective nationwide cohort study included all patients in the National Health Insurance Research Database (NHIRD), who were initially admitted to hospital due to IS between January 1st 2003 and December 31st 2013. The National Health Insurance (NHI) program covers >99% of the population in Taiwan and the NHIRD records the data submitted to the NHI program. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes are used for the registration of all diagnoses, and these data bases are routinely monitored by the NHI Bureau [20]. The patients of interest were restricted to hospitalized patients with a principal diagnosis of IS or transient ischemic attack (ICD-9-CM codes 433-435). Patients without a definite cerebral infarction were not included (ICD-9 codes of 433.00, 433.10, 433.20, 433.30, 433.80, 433.90, 434.90, 434.00, 434.10 and 434.90) [21]. Moreover, the current study focused on the pleiotropic effects of combining T2DM and HTN medications with PPAR-γ modulating properties in IS patients; those without a history of T2DM or HTN were not included. Pioglitazone may induce fluid retention and worsen heart failure (HF), patients with a history of HF were also excluded (Fig. 1). ARB based anti-hypertensive treatment was also required to minimize the class effect of different anti-hypertensive drug categories. All other exclusion criteria are shown in Fig. 1. The Ethics Institutional Review Board of Linkou Chang Gung Memorial Hospital approved the current study (Approval no. 201900714B1).
Exposure to study drugs

The eligible patients were divided into two groups according to the oral antidiabetic agents (OADs) which were prescribed during the 6-month exposure window after the index hospitalization: (1) pioglitazone and (2) non-pioglitazone groups. In the other words, we adopted a ‘pseudo-placebo’ comparison group instead of the active comparator design. Medication was extracted from the claims data of outpatient visits or the refill for chronic illness in the pharmacy. Patients were determined to be users if the study drugs (pioglitazone or OADs) were prescribed twice (or more) in outpatient visits or once (or more) in the refill of the pharmacy. To ensure the consistent use of study drugs in each group, patients were excluded if they took any pioglitazone in the non-pioglitazone group for even 1 day during the 6-month exposure period. For the assessment of adherent medication use, we obtained the medication possession ratio (MPR) calculated by dividing the number of days of medication prescribed (numerator) by the number of days (denominator) during a time period of 6 months (183 days) after index date. The above information was extracted using the date of dispensing and supply in the claims data. Since BP and blood sugar levels were not recorded in the NHIRD, the add-on antihypertensive drugs, the average numbers of antihypertensive drugs and the types of OADs were adjusted to militate the bias associated with different levels of BP and blood sugar [22]. The index hospitalization was later defined as the first hospitalization due to IS throughout the study period.

Ascertainment of IS, HTN and DM

The ICD-9-CM diagnostic codes of IS have been validated in two previous NHIRD studies [20, 23]. The positive predicted values of principal inpatient diagnoses were 88% in these two studies. The diagnostic codes for HTN and T2DM were also validated in a previous NHIRD study [24]. The agreement between diagnoses in
the claims records and self-reports were 93% and 98% for HTM and T2DM, respectively. Besides, the agreement between relevant medications and self-reports was 87% and 95% for HTM and T2DM, respectively [24]. To avoid misclassification bias due to coding errors, the included patients had to meet both the diagnosis and medication requirements.

**Covariates**

The patient's baseline characteristics, including sex, age and hospital level during their index hospitalization, were extracted from the database. Their medical records before the index hospitalization were also obtained to track any history of comorbidities and major health events. Some patients were identified as having at least two outpatient diagnoses or an inpatient diagnosis in the previous year, including coronary artery disease, chronic kidney disease (CKD), chronic obstructive pulmonary disease, atrial fibrillation and dyslipidemia. Dialysis and malignancy were detected using the catastrophic illness certificate database. Previous stroke and myocardial infarction (MI) were detected using any inpatient diagnosis prior to the index date. Most of the diagnostic codes for these events and comorbidities were validated in previous studies (Additional file 1: Table S1) [23, 24]. Charlson Comorbidity Index scores were used to determine the patient's overall systemic health. An estimated National Institutes of Health Stroke Scale (NIHSS) was applied to access the severity of IS; this was validated in a previous NHIRD study [25]. The use of medication including telmisartan was also captured via the Taiwan NHI reimbursement and Anatomical Therapeutic Chemical codes, which was also defined as at least two prescriptions in outpatient visits or any single refill for chronic illness in a pharmacy during the 6-month exposure window. The Anatomical Therapeutic Chemical codes used for the drugs are provided in Additional file 1: Table S2.

**Outcome measurement**

With reference to previous clinical trials [8, 26, 27], the primary outcome was recurrent IS in this study. The secondary outcomes included acute MI, cardiovascular death, all-cause mortality, admission for HF, and bladder cancer. Recurrent IS was adjudicated when patients admitted primarily due to IS during the follow-up period. (Principal diagnosis with ICD-9-CM codes of 433-435 except 433.00, 433.10, 433.20, 433.30, 433.80, 433.90, 434.90, 434.00, 434.10, and 434.90). MI and HF were also judged when patients who were hospitalized principally due to these diagnoses [28]. Death and causes of death were identified according to the registry data of NHIRD. The definition of all-cause mortality and cardiovascular death were the same as those in the registry data of the NHIRD [21, 22]. Bladder cancer was detected in the catastrophic illness certificate database. The follow-up period was calculated from the discharge day of the index hospitalization to the day of death, event occurrence or until December 31st 2013, whichever occurred first.

**Statistical analysis**

The event rate of stroke was 6.5% and 8% in the pioglitazone and placebo groups, respectively, according to a previous randomized trial [8]. Given an alpha level of 5%, a minimum sample size of 9382 patients (4691 in each group) was required to achieve a power of 80%.

Propensity score matching (PSM) was used to balance the distribution of baseline characteristics, and the number of antihypertensive drug classes and OADs used between the two groups. The propensity score was the predicted probability of being in the pioglitazone group given the values of the selected covariates. The covariates used to calculate the propensity score were age, sex, DM duration, events and comorbidities, estimated NIHSS, antihypertensive drug class and OADs, other medications, and the index date (Additional file 1: Table S3). The greedy nearest neighbor matching algorithm was adopted and the caliper was set as 0.2 times the logit of the standard deviation of the propensity score. Replacement after matching was not allowed and the matching order was random. To minimize bias of treatment effect estimation, a 1:2 matching ratio was adopted [29]. The quality of matching was checked using the absolute standardized difference (STD) between the two groups. The propensity score was the average the distribution of baseline characteristics, and the match after matching was not allowed and the matching order was random. To minimize bias of treatment effect estimation, a 1:2 matching ratio was adopted [29]. The greedy nearest neighbor matching algorithm was adopted and the caliper was set as 0.2 times the logit of the standard deviation of the propensity score. Replacement after matching was not allowed and the matching order was random. To minimize bias of treatment effect estimation, a 1:2 matching ratio was adopted [29]. The greedy nearest neighbor matching algorithm was adopted and the caliper was set as 0.2 times the logit of the standard deviation of the propensity score. Replacement after matching was not allowed and the matching order was random. To minimize bias of treatment effect estimation, a 1:2 matching ratio was adopted [29].
agents, insulin, aspirin and clopidogrel. In an additional analysis of pioglitazone and/or telmisartan users, the linear trend of IS risk was tested across different PPAR-γ intensity groups (telmisartan only, pioglitazone only, and pioglitazone plus telmisartan) using a subdistribution hazard model. Likewise, the dose-dependent outcomes across different MPRs of pioglitazone (0%, < 80%, and ≥ 80%) on the risk of recurrent IS was also tested using a linear trend test. The two additional analyses were performed using the whole cohort with adjustments for age, sex, DM duration, all previous events and comorbidities.

Data scientists responsible for the data mining and extraction from the NHIRD were blinded to the design, grouping, and primary interest of this study. The statisticians responsible for data analyses were not blinded to the study design. However, they have received compensation and declared no competing interest between the findings of this study and their company. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA), including the procedures of ‘psmatch’ for propensity score matching, ‘phreg’ for survival analysis and the macro of ‘cif’ for generating cumulative incidence function under the Fine and Gray subdistribution hazard method. Statistical significance was set at \( p < 0.05 \), and no adjustment of multiple testing (multiplicity) was made during the study. The clinical significance of subgroup analyses was loosened to \( p < 0.1 \) because the interaction test was known to be more conservative and less powerful [31].

**Results**

**Study patients**

Between January 1st 2003 and December 31st 2013, a total of 412,047 patients admitted due to IS were available in the NHIRD. Totally 129,557 and 177,918 patients who did not have a history of HTN and T2DM were not included. In addition, 11,114 patients with a history of HF, 12,313 patients whose follow-up duration less than 6 months (including those who died during their index admission), and 11,868 patients who developed recurrent IS or hemorrhagic stroke within 6 months after their index hospitalization were also excluded. A total of 33,345 patients who did not receive any ARB for control of their HTN were also excluded. Finally, 35,835 IS patients were confirmed as eligible for analyses based on the inclusion/exclusion criteria. There were 3190 patients in the pioglitazone group and 32,645 patients in the non-pioglitazone group (Fig. 1).

**Baseline characteristics**

Before the PSM, patients in the pioglitazone group were younger (pioglitazone vs. non-pioglitazone: 67.0 ± 10.0 vs. 68.7 ± 10.4 years old; STD = −0.166) and had a higher prevalence of dyslipidemia (pioglitazone vs. non-pioglitazone: 52.5% vs. 43.5%; STD = 0.180), but had milder estimated NIHSS (pioglitazone vs. non-pioglitazone: 5.3 ± 3.3 vs. 5.9 ± 4.1; STD = −0.165) and shorter follow-up durations (pioglitazone vs. non-pioglitazone: 4.0 ± 2.4 vs. 4.2 ± 2.7 years; STD = −0.104; Additional file 1: Table S3). After PSM, all baseline characteristics and medications were well balanced between the two groups (Table 1). Besides, the duration between index IS hospitalization and the first pioglitazone exposure were 1.4 ± 1.6 months in the pioglitazone group.

**Primary outcome: recurrent ischemic stroke**

The mean follow-up periods were similar between the pioglitazone (4.0 ± 2.4 years) and non-pioglitazone (3.9 ± 2.4 years; STD = 0.022) groups after PSM. The primary outcome was compared between the two study groups. Compared to the non-pioglitazone group, the pioglitazone group had a lower risk of recurrent IS (pioglitazone vs. non-pioglitazone: 18.8% vs. 20.0%; subdistribution hazard ratio [SHR], 0.91; 95% confidence interval [CI] 0.84–0.99; Table 2). In the sensitivity analysis using inverse-probability-of-treatment weighting, the pioglitazone group also had a lower risk of recurrent IS (pioglitazone vs. non-pioglitazone: 19.0% vs. 21.2%; SHR, 0.89; 95% CI 0.80–0.99). The cumulative incidence plot shows lower trends of recurrent IS in the pioglitazone group compared with the non-pioglitazone group (Fig. 2).

**Secondary outcomes**

Compared with the non-pioglitazone group, the pioglitazone group had a lower risk of acute MI (pioglitazone vs. non-pioglitazone: 3.7% vs. 4.2%; SHR, 0.79; 95% CI 0.65–0.97). The risks of all-cause mortality, cardiovascular death, admission for HF, and occurrence of bladder cancer were not significantly different between the two groups at the end of the follow-up (Table 2).

**Subgroup analyses for risks of recurrent IS**

Subgroup analyses defined by various baseline features did not disclose significant alterations to the observed effect of pioglitazone, with the exception of 2 significant interactions (\( p < 0.1 \); Fig. 3). The first interaction was between pioglitazone and a history of CKD before the index event. The second was between pioglitazone and concurrent telmisartan use. The observed effect of pioglitazone in reducing recurrent IS risks was less apparent in patients who had CKD or in those who used ARBs other than telmisartan for BP control.
Table 1  Characteristics of the study patients with and without use of pioglitazone after propensity score matching

| Characteristics                               | Pioglitazone (n = 3189) | Non-pioglitazone (n = 6378) | STD |
|------------------------------------------------|-------------------------|-----------------------------|-----|
| Age, years                                     | 67.0 ± 10.0             | 66.9 ± 10.3                 | 0.008 |
| Age group, n (%)                               |                         |                             |     |
| < 65 years                                     | 1302 (40.8)             | 2615 (41.0)                 | −0.004 |
| 65–74 years                                    | 1151 (36.1)             | 2336 (36.6)                 | −0.011 |
| ≥ 75 years                                     | 736 (23.1)              | 1427 (22.4)                 | 0.017 |
| Male, n (%)                                    | 1580 (49.5)             | 3154 (49.5)                 | 0.002 |
| Admitted in medical center, n (%)              | 957 (30.0)              | 1995 (31.3)                 | −0.028 |
| DM duration, years                             | 8.6 ± 3.4               | 8.6 ± 3.5                   | −0.003 |
| Comorbidity, n (%)                             |                         |                             |     |
| Atrial fibrillation                            | 89 (2.8)                | 154 (2.4)                   | 0.024 |
| Myocardial infarction                          | 90 (2.8)                | 180 (2.8)                   | 0.000 |
| Malignancy                                     | 138 (4.3)               | 288 (4.5)                   | −0.009 |
| Chronic obstructive pulmonary disease          | 197 (6.2)               | 395 (6.2)                   | −0.001 |
| Chronic kidney disease                         | 221 (6.9)               | 466 (7.3)                   | −0.015 |
| Dialysis                                       | 27 (0.8)                | 55 (0.9)                    | −0.002 |
| Old stroke                                     | 282 (8.8)               | 622 (9.8)                   | −0.031 |
| Coronary artery disease                        | 787 (24.7)              | 1594 (25.0)                 | −0.007 |
| Dyslipidemia                                    | 1673 (52.5)             | 3309 (51.9)                 | 0.012 |
| CCI total score                                 | 3.6 ± 1.6               | 3.6 ± 1.6                   | −0.008 |
| Estimated NIHSS                                 | 5.3 ± 3.3               | 5.3 ± 3.2                   | 0.007 |
| Estimated NIHSS group, n (%)                   |                         |                             |     |
| ≤ 5                                            | 2480 (77.8)             | 4958 (77.7)                 | 0.001 |
| 6–13                                           | 556 (17.4)              | 1132 (17.7)                 | −0.008 |
| > 13                                           | 153 (4.8)               | 288 (4.5)                   | 0.013 |
| Anti-hypertensive agent, n (%)                 |                         |                             |     |
| Telmisartan                                    | 246 (7.7)               | 465 (7.3)                   | 0.016 |
| Alpha-blocker                                  | 288 (9.0)               | 580 (9.1)                   | −0.002 |
| Diuretics (thiazide/loop diuretics/spironolactone) | 830 (26.0)             | 1652 (25.9)                 | 0.003 |
| Beta-blocker                                   | 1275 (40.0)             | 2630 (41.2)                 | −0.026 |
| CCB                                            | 1928 (60.5)             | 3835 (60.1)                 | 0.007 |
| Average number of anti-hypertension drugs      | 2.4 ± 1.1               | 2.5 ± 1.1                   | −0.014 |
| Antidiabetic agent, n (%)                      |                         |                             |     |
| Insulin                                        | 560 (17.6)              | 1133 (17.8)                 | −0.005 |
| DPP4i                                          | 576 (18.1)              | 1168 (18.3)                 | −0.007 |
| Secretagogue (Glinide)                         | 578 (18.1)              | 1120 (17.6)                 | 0.015 |
| Alpha glucosidase                              | 828 (26.0)              | 1671 (26.2)                 | −0.005 |
| Biguanide (metformin)                          | 2186 (68.5)             | 4327 (67.8)                 | 0.015 |
| Sulfonylurea                                    | 2408 (75.5)             | 4799 (75.2)                 | 0.006 |
| Other medications, n (%)                       |                         |                             |     |
| Anticoagulant                                   | 102 (3.2)               | 197 (3.1)                   | 0.006 |
| Fibrate                                        | 444 (13.9)              | 907 (14.2)                  | −0.009 |
| Clopidogrel                                     | 532 (16.7)              | 1070 (16.8)                 | −0.003 |
| Statin                                         | 1616 (50.7)             | 3218 (50.5)                 | 0.004 |
| Aspirin                                        | 2431 (76.2)             | 4925 (77.2)                 | −0.023 |
| Follow-up years                                | 40 ± 2.4                | 3.9 ± 2.4                   | 0.022 |
| Propensity score                               | 0.128 ± 0.070           | 0.128 ± 0.070               | 0.002 |

DM diabetes mellitus, CCI Charlson Comorbidity Index, NIHSS National Institutes of Health Stroke Scale, CCB calcium channel blockers, DPP4i dipeptidyl peptidase-4 inhibitor, STD standardized difference

An absolute STD < 0.1 was considered as a non-substantially difference between the groups
Additional analyses: trend test and dose-dependent effect of the intensity of PPAR-γ modulating treatments on IS
A graded correlation was observed between the intensity of PPAR-γ treatment and subsequent IS, with an overall IS rate of 21.7% for patients administered with telmisartan alone, 18.9% for patients with pioglitazone alone and 17.1% for patients with pioglitazone plus telmisartan (Table 3; $p = 0.076$ for linear trend). The dose-dependent outcome for different MPRs in the pioglitazone group also showed a borderline significant trend that higher pioglitazone adherence was associated with a lower cumulative risk of IS (unadjusted event rate: non-pioglitazone group, 21.4%; those with a MPR < 80%, 20.6%; and those with a MPR $\geq$ 80%, 16.4%; $p = 0.068$ for trend).

Discussion
The current nationwide cohort study showed that IS patients taking pioglitazone for T2DM control may have lower risks of recurrent IS during long-term follow-up. Our result supports the protective effects of pioglitazone on IS recurrence in an Asian population. Previous meta-analyses have demonstrated the cardiovascular protective effects of pioglitazone; the IRIS study included...
Fig. 3 Subgroup analyses of recurrent ischemic stroke. Patients without chronic kidney disease had lower risks of recurrent IS in the pioglitazone group ($p$ for interaction = 0.023). Patients using telmisartan for hypertension control may have a lower risk of recurrent IS in the pioglitazone group ($p$ for interaction = 0.071). CI confidence interval, SHR subdistribution hazard ratio, IS ischemic stroke. Statistical significance for interaction of subgroup analyses was set at $p < 0.1$. 

| Subgroup                        | Favor Pioglitazone | Favor Non-pioglitazone | Number of event (%) | SHR (95% CI) | $P$ value for interaction |
|---------------------------------|--------------------|------------------------|---------------------|--------------|--------------------------|
| **Age group**                   |                    |                        |                     |              |                          |
| < 65 years                      |                    |                        | 248 (19.0)          | 2,361 (20.8) | 0.93 (0.80, 1.08)        |
| 65-74 years                     |                    |                        | 216 (18.8)          | 2,658 (23.1) | 0.88 (0.75, 1.03)        |
| ≥ 75 years                      |                    |                        | 134 (18.2)          | 1,954 (20.0) | 1.02 (0.83, 1.27)        |
| **Gender**                      |                    |                        |                     |              |                          |
| Male                            |                    |                        | 300 (19.0)          | 3,499 (21.8) | 0.90 (0.78, 1.03)        |
| Female                          |                    |                        | 298 (18.5)          | 3,474 (21.0) | 0.96 (0.83, 1.10)        |
| **Coronary artery disease**     |                    |                        |                     |              |                          |
| No                              |                    |                        | 431 (17.9)          | 923 (19.3)   | 0.92 (0.82, 1.03)        |
| Yes                             |                    |                        | 167 (21.2)          | 350 (22.0)   | 0.96 (0.80, 1.16)        |
| **Chronic kidney disease**      |                    |                        |                     |              |                          |
| No                              |                    |                        | 547 (18.4)          | 1,190 (20.1) | 0.90 (0.81, 0.99)        |
| Yes                             |                    |                        | 51 (23.1)           | 83 (17.8)    | 1.37 (0.97, 1.95)        |
| **Chronic obstructive pulmonary disease** |      |                        |                     |              |                          |
| No                              |                    |                        | 563 (18.8)          | 1,182 (19.8) | 0.94 (0.85, 1.04)        |
| Yes                             |                    |                        | 35 (17.8)           | 91 (23.0)    | 0.71 (0.48, 1.05)        |
| **Dyslipidemia**                |                    |                        |                     |              |                          |
| No                              |                    |                        | 296 (19.5)          | 624 (20.3)   | 0.95 (0.83, 1.09)        |
| Yes                             |                    |                        | 302 (18.1)          | 649 (19.6)   | 0.91 (0.79, 1.04)        |
| **Estimated NIHSS**             |                    |                        |                     |              |                          |
| ≤ 5                             |                    |                        | 442 (17.8)          | 1,001 (20.2) | 0.87 (0.78, 0.98)        |
| 6-13                            |                    |                        | 123 (22.1)          | 220 (19.4)   | 1.12 (0.90, 1.40)        |
| > 13                            |                    |                        | 33 (21.6)           | 52 (18.1)    | 1.14 (0.74, 1.77)        |
| **Telmisartan**                 |                    |                        |                     |              |                          |
| No                              |                    |                        | 556 (18.9)          | 6,483 (21.3) | 0.95 (0.86, 1.05)        |
| Yes                             |                    |                        | 42 (17.1)           | 490 (21.7)   | 0.68 (0.48, 0.97)        |
| **Thiazide/loop diuretics/ spironolactone** |          |                        |                     |              |                          |
| No                              |                    |                        | 422 (17.9)          | 916 (19.4)   | 0.91 (0.81, 1.02)        |
| Yes                             |                    |                        | 176 (21.2)          | 357 (21.6)   | 0.97 (0.81, 1.16)        |
| **Number of anti-hypertensive agents** |            |                        |                     |              |                          |
| 1-2                             |                    |                        | 312 (17.4)          | 672 (19.0)   | 0.90 (0.79, 1.03)        |
| 3-4                             |                    |                        | 256 (20.6)          | 549 (21.6)   | 0.93 (0.81, 1.08)        |
| ≥ 5                             |                    |                        | 30 (20.3)           | 52 (17.4)    | 1.20 (0.76, 1.88)        |
| **Insulin**                     |                    |                        |                     |              |                          |
| No                              |                    |                        | 481 (18.3)          | 1,036 (19.8) | 0.91 (0.82, 1.02)        |
| Yes                             |                    |                        | 117 (20.9)          | 237 (20.9)   | 0.99 (0.80, 1.24)        |
| **Aspirin**                     |                    |                        |                     |              |                          |
| No                              |                    |                        | 152 (20.1)          | 290 (20.0)   | 0.99 (0.82, 1.21)        |
| Yes                             |                    |                        | 446 (18.3)          | 983 (20.0)   | 0.91 (0.81, 1.01)        |
| **Clopidogrel**                 |                    |                        |                     |              |                          |
| No                              |                    |                        | 475 (17.9)          | 1,039 (19.6) | 0.91 (0.81, 1.01)        |
| Yes                             |                    |                        | 123 (23.1)          | 234 (21.9)   | 1.01 (0.81, 1.26)        |
non-diabetic patients with IR based on a homeostasis model assessment of insulin resistance score and demonstrated lower stroke or MI in patients with pioglitazone use than in the others receiving placebo. However, the difference in stroke risk reduction alone was not statistically significant between the two groups [8]. Although the subgroup analysis of the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) study showed that pioglitazone could reduce the risk of recurrent stroke in T2DM patients [26], but only 19% of the enrolled patients in this study had previous stroke and this may limit the conclusive answers of the subgroup analysis [7]. Therefore, for T2DM patients with a previous stroke, more clinical data may be needed to support the protective effects of pioglitazone on secondary prevention. Besides, these conclusions should be interpreted cautiously when applied to Asian population. In theory, Asian IS patients are more vulnerable to have recurrent IS, however the recruitment of Asian patients in these studies was insufficient. The Junteno Stroke Prevention study in Insulin Resistance and Impaired glucose Tolerance did not show a significant protective effect of pioglitazone in Japanese [27]. Nevertheless, the number of enrolled patients in that study was too small. The IRIS study also failed to demonstrate sufficient protective effects of pioglitazone in Asian patients [8, 27]. In Asian T2DM patients without prior cardiovascular diseases, the real-world data also showed controversial protective effects of pioglitazone. Chan et al. [32] demonstrated that pioglitazone added to metformin, compared to sulfonylurea plus metformin, may have fewer major cardiovascular events in T2DM patients. But another real-world study did not show the protective effects of pioglitazone on IS prevention [33]. In Asian T2DM patients with previous strokes, a Korea nested case–control study demonstrated a benefit of pioglitazone on composite cardiovascular outcomes but not on recurrent IS [12]. As a result, the strength of our nationwide cohort study showed that Asian patients with IS taking pioglitazone for T2DM could lower the risks of recurrent IS during the long-term follow-up. Our data provided the evidence of pioglitazone for secondary prevention of IS in Asian T2DM patients, which was compatible with the findings of cardiovascular protection from previous meta-analyses [7, 11, 34]. Furthermore, the current study revealed that IS patients without CKD or concurrent telmisartan use for BP control may have trends of obtaining more benefits when taking pioglitazone for T2DM.

It is well known that PPAR-γ may have metabolism regulating and neuroprotective effects and could have protective effects for HTN, atherosclerosis and CKD [5, 6, 35]. Pioglitazone, a potent PPAR-γ agonist, has demonstrated vascular protective effects in previous studies [7, 8, 11]. Pioglitazone may show potential beneficial effects on anti-inflammation, neuroprotection, and neurogenesis in cerebral ischemia animal studies [36, 37]. Moreover, pioglitazone may raise adiponectin level. The elevated adiponectin level could be associated with increased energy consumption and insulin sensitivity [38]. The elevated adiponectin might also have anti-inflammatory, anti-atherosclerotic, and anti-thrombotic effects [39]. Telmisartan may also promote the secretion of adiponectin [40]. But the correlations between adiponectin levels and clinical outcomes remain controversial and may need further investigations [41, 42]. Furthermore, it remains unknown whether the more potent PPAR-γ modulating effects may provide better vascular protective effects. Between the two clinically available thiazolidinediones, rosiglitazone has the most potent PPAR-γ activation [43]. Different from pioglitazone, rosiglitazone has an unfavorable effect on atherogenic lipid profiles with a greater elevation of low-density lipoprotein cholesterol and

| Table 3 Trend test and dose-dependent effect of the intensity of PPAR-γ modulating treatments on risk of recurrent ischemic stroke by using the whole cohort before matching |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Patient number** | **No. of event (%)** | **p trend** | **p trend‡** |
|-----------------|-----------------|-----------------|-----------------|
| Trend test of telmisartan and pioglitazone effect | | 0.087 | 0.076 |
| Pioglitazone plus telmisartan | 246 | 42 (17.1) | |
| Pioglitazone alone | 2944 | 556 (18.9) | |
| Telmisartan alone | 2259 | 490 (21.7) | |
| Dose-dependent effect of pioglitazone | | 0.015 | 0.068 |
| MPR ≥ 80 | 1406 | 231 (16.4) | |
| MPR < 80 | 1784 | 367 (20.6) | |
| Non-pioglitazone | 32,645 | 6973 (21.4) | |

PPAR-γ peroxisome proliferator-activated receptor-gamma, MPR medication possession ratio
Statistical significance was set at *p < 0.05*
‡ Adjusted for all the variables listed in Table 1, except medications, follow-up years and the propensity score
triglyceride, which could contribute to adverse outcomes and increase cardiovascular risks [33, 44]. Similarly, pioglitazone can increase low-density lipoprotein cholesterol over time. But it also increases high-density lipoprotein cholesterol levels, decreases triglyceride level, and has unremarkable changes in non-high-density lipoprotein cholesterol levels [45]. In our study, it was observed that the prevalence of dyslipidemia was substantially higher in the pioglitazone group than in the non-pioglitazone group before matching, therefore the patients who received pioglitazone were more likely to have a higher risk of recurrent IS. However, this effect may have been mitigated after matching because the prevalence of dyslipidemia was balanced between groups. If this indication bias actually existed, then the observed beneficial effect of pioglitazone on prevention of recurrent IS may be somewhat under-estimated in this study.

Telmisartan is a partial PPAR-γ agonist and is the only ARB that yields PPAR-γ modulating effects under clinical doses [46]. However, the PPAR-γ modulating effect of telmisartan remains much lower than that of pioglitazone [14, 46]. Therefore, telmisartan has not shown significant stroke preventive effects in previous studies [47, 48]. Telmisartan binds with the PPAR-γ receptor in a different way from pioglitazone, it is rational to use these two drugs concurrently in clinical practice [49]. Previous studies have proved the safety of combining these PPAR-γ modulating drugs [18, 19]. However, there was no clinical study designed specifically to examine the effect of combining these drugs on stroke prevention. The real-world data used in the current study, revealed that compared with those taking ARBs other than telmisartan, patients receiving telmisartan for BP control tended to have less recurrent IS ($p$ for interaction $=0.071$). The study further demonstrated a borderline significant trend of fewer upcoming IS events following the combined use of pioglitazone and telmisartan, compared with the use of pioglitazone or telmisartan alone ($p$ for trend $=0.076$). These results suggest there could be a protective effect from using more intensive PPAR-γ modulating regimens for IS patients with T2DM and HTN. Pioglitazone adherence is an important factor contributing to IS prevention [50]. Our data echoed the post hoc analysis of the IRIS study which showed the hazard ratio of recurrent IS could be lower in the patients of the subgroup with pioglitazone adherence $\geq 80\%$ than in those of the intention-to-treat analysis [50]. A clinical trial is warranted to confirm or refute the casual relationship of such combination therapy.

Chronic kidney disease is an independent risk factor for carotid atherosclerosis and stroke [51], which might be related to vascular calcification, endothelial dysfunction, and impaired drug effects for secondary stroke prevention in these patients [51]. IR is also a cardiovascular risk factor in patients with CKD [52]. Pioglitazone activates PPAR-γ and hence may improve IR in patients with CKD [53]. The vascular protective effect of pioglitazone in CKD patients was unknown in the IRIS study [53]. However, data from the PROactive study demonstrated that CKD patients treated with pioglitazone for T2DM may have higher all-cause death, MI and stroke when compared to non-CKD patients [7, 54]. There is very limited real-world data comparing pioglitazone use between CKD and non-CKD patients. Similar to the PROactive trial, our study also showed that non-CKD patients may have more benefits on IS prevention from pioglitazone use ($p$ for interaction $=0.023$). At low doses, when compared to standard doses, pioglitazone is associated with comparable glycemic control but with reduced weight gain and fluid retention in CKD patients [55]. The drug adherence of pioglitazone could be lower in CKD patients in clinical practice because CKD is a major predictor of hospitalization for HF [56]. However, our data showed both the MPR (CKD vs. non-CKD: $67.3 \pm 31.8\%$ vs. $64.0 \pm 33.8\%; p=0.157$) and mean doses (CKD vs. non-CKD: $18.3 \pm 11.1$ vs. $18.2 \pm 12.3$ mg/day; $p=0.932$) of pioglitazone were similar between the CKD and non-CKD patients of the pioglitazone group. Our results suggest the decreased protective effect of pioglitazone in CKD patients may come from the cardiovascular risks of renal disease itself rather than the insufficient drug compliance in these patients.

In line with previous reports, the current data also showed a lower incidence of MI in pioglitazone users [57]. Although the potential risks of HF and bladder cancer in pioglitazone users have gained clinical attention [58, 59], the issue of increasing risks of bladder cancer remains unconfirmed due to the conflicting results from previous studies [58–60]. In the present study, using the real-world data in Taiwan, the increased risk of newly diagnosed bladder cancer in the pioglitazone group was substantial by 34% (HR $=1.34$) but not statistically significant due to the limited sample size. Although whether pioglitazone could lead to an increased risk of bladder cancer is with doubtful evidences, Food and Drug Administration in the United States announced that pioglitazone should not be used in patients with active bladder cancer [61]. Therefore, in patients with a history of bladder cancer, the benefits of pioglitazone, such as stroke prevention versus the possible risks of cancer recurrence should be considered carefully and pioglitazone is probably under-utilized in our real-world practice [62].

There were some limitations to the present study. First, the homeostasis model assessment of the insulin resistance index, blood sugar and BP levels were not
available in the claims database. The stroke severity of the included patients was also not known. Besides, patients who developed recurrent minor IS without hospitalization were not registered in this data. Patients were followed after a 6-month exposure window of the OADs, therefore high-risk patients who were vulnerable to develop recurrent IS within 6 months after index hospitalization were excluded in this study. All of these may lead to selection bias of the study population and data interpretation. This study was also unable to demonstrate the short-term effect of pioglitazone and intensive PPAR-γ-modulating treatment on risks of recurrent IS during the 6-month follow-up after the index IS, and a clinical trial in the future is warranted to answer this question. However, some efforts were made to mitigate these selection biases, residual or unmeasured confounders. The estimated NIHSS, the number of anti-hypertensive drug agents and antidiabetic drugs used at baseline, and the Charlson Comorbidity Index were used to be proxies of stroke severity index, BP control and glucose control, respectively. Second, drug switching, combinations, and adherence may confound the results. In the real-world study, we can only speculate the drug adherence and compliance through prescription records. Unlike clinical trials, we can hardly obtain the actual medication-taking behavior of patients and the drug prescription behavior of physicians in claims data. However, all the insurance claims are reviewed and inspected by medical reimbursement specialists in Taiwan. Physicians and their institutions are penalized if they violate clinical guidelines. In addition, we examined the association between different MPRs and IS events in the present study. This may reduce the bias that might influence the conclusions. Third, the statistical analysis may be underpowered due to limited sample size, even though this has been a population-based study. For some physicians, ARBs may not be their drug of choices for hypertensive control in IS patients. However, this national cohort data could be the largest available one we can achieve to answer this unknown question so far. Fourth, the ICD-9-CM may have been coded incorrectly in the claims database. However, validation studies have been conducted previously by linking this coding method and the stroke registry. Fifth, the causal effects of these study drugs should be interpreted cautiously in this observational study. Population-based observational studies support a lower standard of evidence than randomized control trials. The exploratory results of our observational study remained insufficient to give conclusive answers. However, our findings could help to motivate future studies on more potent PPAR-γ-modulating treatment in IS patients. Lastly, the generalizability of these conclusions to other ethnicities is unclear.

Conclusion
The current study suggests that the use of pioglitazone in IS patients with T2DM and HTN is associated with fewer recurrences of IS in an Asian population. Those who have concurrent telmisartan use or a higher MPR may have a trend of more pleiotropic effects, which might be associated with higher PPAR-γ effects. Clinical trials and basic researches should be conducted to confirm or refute the potential effects of more intensive PPAR-γ-modulating treatments upon clinical outcomes in hypertensive T2DM patients after IS and the possible mechanism.

Supplementary information

Additional file 1: Table S1. ICD-9-CM code used for diagnosis in the current study. Table S2. Anatomical Therapeutic Chemical (ATC) codes used for drugs in the current study. Table S3. Characteristics of the study patients with and without use of pioglitazone before propensity score matching.

Abbreviations
PPAR-γ: peroxisome proliferator-activated receptor-γ; T2DM: type 2 diabetes mellitus; IS: ischemic stroke; IR: insulin resistance; OADs: oral antidiabetic agents; HTN: hypertension; ARBs: angiotensin receptor blockers; BP: blood pressure; CKD: chronic kidney disease; MPR: medication possession ratio; MI: myocardial infarction; HF: heart failure; NHIRD: National Health Insurance Research Database; NIHSS: National Institutes of Health Stroke Scale; PSM: propensity score matching; STD: standardized difference; SHR: subdistribution hazard ratio; CI: confidence interval.

Acknowledgements
The authors would like to thank Alfred Hsing-Fen Lin, MS, and Zoe Ya-Jhu Syu, MPH, Raising Statistics Consultant Inc, for their statistical assistance. These individuals received compensation and declared no competing interest between the findings of this study and (these individuals) their company. The authors would also like to thank Chang Gung Memorial Hospital and Ms. Elaine Shin-wei Huang for her administrative work.

Authors’ contributions
(1) Conception and design of the study: CHL, YRL. (2) Acquisition and analysis of data: CHL, YRL, YSL, THL, PSS, YCW. (3) Drafting a significant portion of the manuscript or figures: CHL, YRL, THL, YSL. All authors read and approved the final manuscript.

Funding
The current study was supported by Ministry of Science and Technology (Grant number: MOST 108-2314-B-182A­050-MY3 and NMRRPG3J6131) and Chang Gung Memorial Hospital research project [Grant numbers: CMRPG3F and BMPPF99 (CH Liu), CMRPG3F221 (TH Lee)].

Availability of data and materials
The datasets used and analyzed in our study are available from the corresponding author on reasonable requests.

Ethics approval and consent to participate
The protocol of this study and informed consent of all participants were approved by the Ethics Institutional Review Board of Linkou Chang Gung Memorial Hospital (Approval no. 20190071481).
Consent for publication
Authors give full consents for publication of the present article.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Stroke Center and Department of Neurology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. 4 College of Medicine, Chang Gung University, Taoyuan, Taiwan. 2 Division of Cardiology, Department of Internal Medicine, Chiai Chang Gung Memorial Hospital, Chiai, Taiwan. 5 Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan. 3 Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. 6 Department of Neurology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan. 7 Institute of Neuroscience, National Yang-Ming University, Taipei, Taiwan. 8 Division of Endocrinology and Metabolism, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, and College of Medicine, Chang Gung University, No. 5, Fu-Hsing St, Kueshian, Taoyuan 33333, Taiwan.

Received: 13 October 2019 Accepted: 24 December 2019
Published online: 07 January 2020

References
1. Ago T, Matsuo R, Hata J, Wakisaka Y, Kuroda J, Kitazono T, et al. Insulin resistance and clinical outcomes after acute ischemic stroke. Neurology. 2018;90(17):e1470–7.
2. Jing J, Pan Y, Zhao X, Zheng H, Jia Q, Mi D, et al. Insulin resistance and prognosis of nondiabetic patients with ischemic stroke: the ACROSS-China Study (abnormal glucose regulation in patients with acute stroke across china). Stroke. 2017;48(4):887–93.
3. Deng XL, Liu Z, Wang C, Li Y, Cai Z. Insulin resistance in ischemic stroke. Metab Brain Dis. 2017;32(5):1323–34.
4. Liu J, Wang LN. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischemic attack. Cochrane Database Syst Rev. 2017;12:CD010693.
5. Kaundal RK, Sharma SS. Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. Drug News Perspect. 2010;23(4):241–56.
6. Han L, Shen WJ, Bittner S, Kraemer FB, Azhar S. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-beta/delta and PPAR-gamma. Future Cardiol. 2017;13(3):279–96.
7. Dормandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89.
8. Kennan WN, Viscotti CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374(14):1321–31.
9. Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5(11):887–97.
10. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Effects of pioglitazone versus sulfonylureas in patients with type 2 diabetes in the PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events) study: a systematic review and meta-analysis. Stroke. 2007;38(3):865–73.
11. Chen CL, Lee CH, Chen PS, Li YH, Lin SJ, Yang YH. Validation of acute myocardial infarction cases in the national health insurance research database in Taiwan. J Epidemiol. 2014;24(6):500–7.
12. Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol. 2010;172(9):1092–7.
13. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004;109(17):2054–7.
14. Takagi H, Umemoto T, All-Literature Investigation of Cardiovascular Evidence G. A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients. J Am Soc Hypertens. 2014;8(8):578–92.
15. Wang Y, Qiao S, Han DW, Rong XR, Wang YX, Yue JJ, et al. Telmisartan improves insulin resistance: a meta-analysis. Am J Ther. 2018;25(6):e642–51.
16. Ernsterberger P, Koletsky RJ. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Curr Opin Pharmacol. 2007;7(2):140–5.
17. Shahataa MG, Mostafa-Hedeab G, Ali EF, Mahdi EA, Mahmoud FA. Effects of telmisartan and pioglitazone on high fructose induced metabolic syndrome in rats. Can J Physiol Pharmacol. 2016;94(8):907–17.
18. Sengupta P, Chatterjee B, Pat TK. Assessment of preclinical pharmacokinetics and acute toxicity of pioglitazone and telmisartan combination. Regul Toxicol Pharmacol. 2017;91:151–8.
35. Sugawara A, Urano A, Kudo M, Matsuda K, Yang CW, Ito S. Effects of PPAR-gamma on hypertension, atherosclerosis, and chronic kidney disease. Endocr J. 2010;57(10):847–52.

36. Gliem M, Klotz L, van Rooijen N, Hartung HP, Jander S. Hyperglycemia and PPAR gamma antagonistically influence macrophage polarization and infract healing after ischemic stroke. Stroke. 2015;46(10):2935–42.

37. Kinouchi T, Kitazato KT, Shimada K, Yagi K, Tada Y, Matsuishi N, et al. Treatment with the PPAR gamma agonist pioglitazone in the early post-ischemia phase inhibits pro-inflammatory responses and promotes neurogenesis via the activation of innate- and bone marrow-derived stem cells in rats. Transl Stroke Res. 2018;9(3):306–16.

38. Yadav A, Kataria MA, Saini V, Yadav A. Role of leptin and adiponectin in insulin resistance. Clin Chim Acta. 2013;417:80–4.

39. Gaitella J, Kler R, Modii M, Khurana D. Leptin and adiponectin: pathophysiological role and possible therapeutic target of inflammation in ischemic stroke. Rev Neurolsci. 2017;28(3):295–306.

40. Fang T, Di Y, Li G, Cui X, Shen N, Li Y, et al. Effects of telmisartan on TNFalpha induced PPARgamma phosphorylation and insulin resistance in adipocytes. Biochem Biophys Res Commun. 2018;503(4):3044–9.

41. Mori D, Miyagawa S, Matsuura R, Sougawa N, Fukushima S, Ueno T, et al. Pioglitazone strengthens therapeutic effect of adipose-derived regenerative cells against ischemic cardiomyopathy through enhanced expression of adiponectin and modulation of macrophage phenotype. Cardiovasc Diabetol. 2019;18(1):39.

42. Wang Z, Li B, Wang Y, Maimartili A, Qin H, Dangmurenjiafu G, et al. The association between serum adiponectin and 3-month outcome after ischemic stroke. Cardiovasc Diabetol. 2019;18(1):105.

43. Chakrabarti R, Vikramadithyan RK, Misra P, Hiriyan J, Raichur S, Malar KA, et al. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol. 2003;140(3):527–37.

44. Deeg MA, Tan MH. Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies. PPAR Res. 2008;2008:20465.

45. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28(7):1547–54.

46. Benson SC, Pershad Singh HA, Ho CI, Chittraboyina A, Desai P, Praveen M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004;43(5):993–1002.

47. Yusuf S, Diener HC, Sacco RL, Cotton D, Dunpaw S, Lawton WA, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359(12):1225–37.

48. Diener HC. Preventing stroke: the PROFESS, ONTARGET, and TRANSCEND trial programs. J Hypertens Suppl. 2009;27(5):S31–6.

49. Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu A, et al. A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology. 2009;150(2):862–70.

50. Spence JD, Viscoli CM, Inzucchi SE, Dearborn-Tomazos J, Ford GA, Gorman M, et al. Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the IRIS randomized clinical trial. JAMA Neurol. 2019;76(5):526–35.

51. Toyoda K, Ninomiya T. Stroke and cerebrovascular diseases in patients with chronic kidney disease. Lancet Neurol. 2014;13(8):823–33.

52. Chan DT, Watts GF, Irish AB, Dogra GK. Insulin resistance and vascular dysfunction in chronic kidney disease: mechanisms and therapeutic interventions. Nephrol Dial Transplant. 2017;32(8):1274–81.

53. Xu H, Carrero JJ. Insulin resistance in chronic kidney disease. Nephron. 2017;22(Suppl 4):31–4.

54. Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol. 2008;19(1):182–7.

55. Satirapoj B, Watanakijthavonkul K, Supasynhod O. Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: a randomized controlled trial. PLoS ONE. 2018;13(10):e0206722.

56. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579–88.

57. Young LH, Viscoli CM, Curtis JP, Inzucchi SE, Schwartz GG, Lovejoy AM, et al. Cardiac outcomes after ischemic stroke or transient ischemic attack: effects of pioglitazone in patients with insulin resistance without diabetes mellitus. Circulation. 2017;135(20):1882–93.

58. Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, et al. Heart failure after ischemic stroke or transient ischemic attack in insulin-resistant patients without diabetes mellitus treated with pioglitazone. Circulation. 2018;138(12):1210–20.

59. Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314(3):265–77.

60. Ripamonti E, Azoulay L, Abrahamowicz M, Platt RW, Saisa S. A systematic review of observational studies of the association between pioglitazone use and bladder cancer. Diabet Med. 2019;36(1):22–35.

61. FDA Drug Safety Communication. Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. http://www.fda.gov/Drugs /DrugSafety /ucm259150.htm. Accessed 14 Dec 2019.

62. Piantoni L. Potential new horizons for the prevention of cerebrovascular diseases and Dementia. JAMA Neurol. 2019;76(5):S21–2.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research?** Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](http://biomedcentral.com/submissions)